FDA records linked by MedtechLedger identify Qure.Ai Technologies Pvt., Ltd. as the applicant on K261517 for radiology software. The sources also include a K240740 letter addressed to Qure.ai Technologies, which does not print the same legal suffix. K261517 covers qCT Lung (v1.0), a device regulated under 21 CFR 892.2090 with product code QDQ and a Substantially Equivalent decision dated September 14, 2026. The earlier K240740 covers qCT LN Quant under 21 CFR 892.2050 with product code QIH. Both filings list a Mumbai, India address for the applicant. The records describe device identities and review scope; they do not establish corporate ownership, commercial availability or clinical performance. [1][2][5]
qCT Lung (v1.0) and its cleared scope
The K261517 record lists qCT Lung (v1.0) as a Traditional premarket notification received May 7, 2026, with a decision date of September 14, 2026 and a decision description of Substantially Equivalent. The advisory committee is Radiology, the device class is 2, and the submission was not reviewed by a third party. The FDA database entry also notes that a Predetermined Change Control Plan was authorized. [1][3]
The FDA decision letter states the intended use: qCT Lung is a diagnostic image analysis tool intended for use as a concurrent reader for the analysis of CT scans from a lung cancer screening population. It assists radiologists and pulmonologists in the detection of pulmonary nodules of size 4-30 mm and provides characterization and quantification of the region of interest. The letter identifies the regulation as 21 CFR 892.2090, Radiological Computer-Assisted Detection And Diagnosis Software. [2]
qCT LN Quant and the earlier clearance
K240740, dated August 16, 2024, names qCT LN Quant as the trade/device name, regulated under 21 CFR 892.2050 as a Medical Image Management And Processing System in Class II with product code QIH. The letter is addressed to a Qure.ai Technologies regulatory contact at a Goregaon (E), Mumbai address, which differs from the Andheri (East) address in the K261517 record. [5]
The K240740 decision letter states that verification and validation testing was executed and documentation provided as recommended by FDA guidance on premarket submission content for device software functions. It reports that qCT LN Quant functioned as designed and met anticipated performance criteria during those tests. That statement describes the applicant's submitted testing, not independent clinical validation. [5]
Company-published material and its limits
A Qure.ai blog post published August 11, 2021 describes qCT-Lung as an AI product that analyses chest CT scans for lung cancer and places it alongside qXR for chest X-rays and qTrack. The post states a company vision of using artificial intelligence to make healthcare more accessible and affordable. These are manufacturer statements about product positioning, not FDA findings. [7]
A qSuite Instructions for Use document dated January 20, 2023, version 1.0, is published under Qure.ai Technologies Pvt Ltd with a Goregaon (E), Mumbai address. It reports segmentation algorithm performance figures, including a lung segmentation value of 0.99 with a stated range. Those figures belong to that document and are not attributed here to qCT Lung or qCT LN Quant. [8]
Qure.ai's regulatory and privacy page states a commitment to quality, safety and regulatory compliance and refers to certifications and standards without listing them in the retrieved text. The page footer carries a corporate identification number and a 2023 copyright notice. It does not document device-level clearances. [9]
What the filing record does and does not show
The linked collection contains one 510(k) record, K261517, with a single Substantially Equivalent decision; the record sample is the same single entry. That count reflects the retrieved filings as of the snapshot date and is not a measure of total company sales, total portfolio or safety performance. The K240740 letter appears in the numbered sources but is not part of that linked collection count. [1][5]
The applicant name on K261517 is Qure.Ai Technologies Pvt., Ltd. The K240740 letter uses Qure.ai Technologies without the Pvt., Ltd. suffix, so the two name forms are retained as printed rather than treated as verified identical legal entities. The sources do not establish a parent company, brand ownership structure or commercial availability of either device. Filing addresses are correspondence addresses in FDA records and are not treated here as a headquarters designation. [1][2][5]
